ASPEN PHARMACARE HOLDINGS LIMITED - Grant and Acceptance of Share Awards by a Director and Prescribed Officer of the Company
What this filing means
A routine incentive award disclosure. Aspen granted 30,000 deferred shares each to director Sean Matthew Capazorio and prescribed officer Lorraine Angela Hill under the Long-term Retention Scheme, at R163.16 per share — a combined deemed value of R9.79 million. The grant price is based on the three-day VWAP on 6 November 2026. This is standard compensation mechanics, not a market signal.
Aspen awarded 30,000 deferred incentive shares each to a director and a prescribed officer under the Long-term Retention Scheme. The grant price is based on Aspen's three-day VWAP on 6 November 2026, so the awards are valued at a market-referenced price rather than a discount. The filing does not disclose the applicable vesting or holding-period terms.
AI-generated summary by SENS-AI, based on the original JSE SENS filing.
SENS-AI conclusion
This is a mechanical disclosure of share awards under an existing scheme, not a fresh economic signal. The awards align the two individuals with longer-term retention, but off-market grants carry no insider conviction signal the way an open-market purchase would. So what: nothing here changes the investment case; the market still needs the next results or a substantive operational update to reprice the name.
The next results announcement is where the market will test whether the retention scheme is working and whether operating performance supports the recent run.
Evidence from the filing
Director Sean Matthew Capazorio accepted an off-market award of 30,000 deferred incentive shares at R163.16, with a deemed transaction value of R4,894,800.00.
“Director : Sean Matthew Capazorio Date of transaction : 19 November 2026 Nature of transaction : Off-market award and acceptance of deferred incentive shares under the Long-term Retention Scheme Number of securities : 30,000 Grant price* : R163.16 Deemed value of transaction : R4,894,800.00 Class of securities : Ordinary shares Nature of interest : Direct beneficial Clearance obtained : Yes”
More on Aspen Pharmacare Holdings Limited
Related filings
More from APN
- ASPEN PHARMACARE HOLDINGS LIMITED - Regulatory Approvals for Aspens Generic Injectable Semaglutide in Brazil and South Africa
- ASPEN PHARMACARE HOLDINGS LIMITED - Notification in terms of Section 122 (3)(b) of the Companies Act and Section 6.54 of the JSE Listings Requirements
- ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Director, Prescribed Officer and the Company Secretary of Aspen and the Company Secretary of a Major Subsidiary of Aspen
- ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Prescribed Officer
- ASPEN PHARMACARE HOLDINGS LIMITED - Grant and Acceptance of Share Awards by Directors, Prescribed Officers and The Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
Other Share Incentive Scheme Award
- WBOWILSON BAYLY HOLMES-OVCON LIMITED - Directors Dealings: Vesting of the 2023 Allocation of the 2013 WBHO Share Plan
- ADRADCORP HOLDINGS LIMITED - Dealings by the Adcorp long-term incentive (LTI) plan
- APNASPEN PHARMACARE HOLDINGS LIMITED - Grant and Acceptance of Share Awards by Directors, Prescribed Officers and The Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
- OMUOLD MUTUAL LIMITED - Dealings in Securities on behalf of Employee Share Incentive Schemes
- OMUOLD MUTUAL LIMITED - Old Mutual - Dealings in Securities on behalf of Employee Share Incentive Schemes - OMLI